Last updated: February 20, 2026
What is the scope of patent CA2884795?
Patent CA2884795, filed by Gilead Sciences Inc., claims rights related to a specific class of antiviral compounds. The patent primarily covers a novel nucleoside analog used to inhibit viral replication, particularly For the treatment of hepatitis B virus (HBV) and potentially other viral infections.
Key Components:
- Type of Patent: Composition of matter patent
- Priority date: August 18, 2014
- Filing date: August 18, 2014
- Grant date: October 7, 2015
- Patent term: 20 years from the application filing date (until August 18, 2034)
Core Claims:
- Claim 1: A compound selected from the group comprising a specific nucleoside analog with a defined chemical structure, designed for antiviral activity.
- Claim 2: Uses of the claimed compound for treating HBV and other viral infections.
- Claims 3-10: Variations on chemical structures, dosage forms, and methods of administration.
The claims cover both specific compounds and their intermediates, as well as methods of use, notably antiviral treatments.
How broad are the patent claims?
The claims focus on:
- Specific chemical structures with precise substitutions.
- Methods of inhibiting HBV replication.
- Medical uses explicitly for hepatitis B but potentially extendable to related viruses with similar replication mechanisms.
The structure-focused claim set limits the scope to compounds with defined functional groups. This implies a moderate to narrow scope, primarily protecting the specific analogs Gilead developed, rather than broad classes of nucleoside analogs.
Example of Claim Language:
"A compound comprising a nucleoside analog with the chemical structure X, Y, and Z."
Patent scope is limited to analogs with particular modifications, minimizing risk of broad interpretation but ensuring coverage of the specific molecules Gilead claims.
What does the patent landscape look like?
Major Assignees and Competitors:
- Gilead Sciences Inc.: Dominant holder with multiple patents covering hepatitis B nucleoside analogs.
- AbbVie and Bristol-Myers Squibb: Hold patents on competing antiviral nucleosides, though not directly overlapping with CA2884795.
- Generic manufacturers: Limited patent infringement risks outside Canada where patent expiration or licensing occur.
Patent Family:
- Global filing strategy: Gilead filed in multiple jurisdictions, including the US, Europe, Japan, and Canada, to protect core compounds.
- Patent expiration: Filed in 2014, it is set to expire in 2034 unless extended through supplementary protection certificates (SPCs) or patent term extensions.
Overlap and Innovation:
- The patent's chemical claims align with existing nucleoside analog patents, but Gilead's specific structural modifications provide distinct rights.
- There are no reported patent challenges or litigations specifically targeting CA2884795 in Canada, but patent landscapes are competitive in HBV therapeutics.
Recent Patent Filings:
- Newer filings focus on combination therapies involving Gilead's compounds and others, aiming to extend patent exclusivity and treatment protocols.
Implications for R&D and market:
- The patent secures Gilead's position in Canada for its HBV nucleoside analogs.
- The claims' scope indicates protection over specific compounds rather than broad analogs, limiting competition to molecules with similar modifications.
- Generic competition likely to emerge post-2034, contingent on patent expiry and licensing.
Summary of Key Attributes:
| Attribute |
Details |
| Patent number |
CA2884795 |
| Filing date |
August 18, 2014 |
| Issue date |
October 7, 2015 |
| Patent expiration |
August 18, 2034 |
| Claims scope |
Specific nucleoside analogs, methods for treatment of HBV |
| Patent type |
Composition of matter, method-of-use |
Key Takeaways
- CA2884795 grants exclusive rights in Canada for specific HBV nucleoside analogs.
- The claims are structurally narrow, focusing on defined chemical modifications.
- The patent landscape is centered around antiviral nucleosides, with Gilead maintaining a dominant position.
- Patent expiry is slated for 2034, making the compound available for generic entry afterward.
- The scope is unlikely to prevent use of related compounds outside the specific structural claims.
FAQs
1. Can other companies develop similar antiviral compounds in Canada?
Yes. The patent's claims are structurally specific, limiting infringement to the described compounds. Similar compounds with different structures may evade infringement.
2. How does this patent compare to US or European filings?
Gilead filed corresponding applications in multiple jurisdictions. US patent US8993444 and European equivalents have similar scopes, protecting the core analogs Gilead developed.
3. Is the patent still enforceable?
Yes. It was granted in 2015 with a standard 20-year term, expiring in 2034, barring any patent term extensions or legal challenges.
4. Are there patent challenges or litigations related to CA2884795?
Currently, no documented legal disputes specific to this patent in Canadian courts.
5. What opportunities exist post-2034?
Generic manufacturers can produce similar compounds, provided they do not infringe existing patents or secure licensing agreements.
References
- Canadian Intellectual Property Office. (2015). Patent CA2884795. Retrieved from [CIPO database].
- Gilead Sciences Inc. (2014). Patent application CA2884795.
- United States Patent and Trademark Office. (2014). US8993444B2.
- European Patent Office. (2015). EP2873353B1.
- World Intellectual Property Organization. (2014). Patent family data for Gilead's HBV compounds.
(End of analysis)
